This was used in patient-derived iPSCs to modify alternative splicing in the MAPT gene, aiming to counteract pathogenic mutations associated with Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). This evidence concerns the gene MAPT and Parkinsonism.